港股异动 | 康方生物(09926)早盘涨近5% 曼多奇单抗(IL-4Rα)新药上市申请获受理

Core Viewpoint - Kangfang Biopharma (09926) has submitted a New Drug Application (NDA) for its IL-4Rα monoclonal antibody (Mandokizumab, AK120) to the National Medical Products Administration (NMPA) for the treatment of moderate to severe atopic dermatitis (AD) [1] Group 1 - Kangfang Biopharma's stock rose nearly 5% in early trading, reaching a price of 106.2 HKD with a trading volume of 456 million HKD [1] - The submission of the NDA for Mandokizumab marks the fourth non-oncology drug that the company has entered the application stage for [1] - The company has previously received approvals or submitted applications for other monoclonal antibodies, including PCSK9 monoclonal antibody Inusimab, IL-12/IL-23 monoclonal antibody Iroquois, and IL-17A monoclonal antibody Gumokizumab, creating a diverse product matrix covering cardiovascular metabolism, skin, and joint diseases [1]